🇺🇸 Perindopril + Indapamide in United States

160 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 160

Most-reported reactions

1. Acute Kidney Injury — 22 reports (13.75%)
2. Asthenia — 18 reports (11.25%)
3. Fatigue — 17 reports (10.62%)
4. Hyponatraemia — 17 reports (10.62%)
5. Vomiting — 16 reports (10%)
6. Diarrhoea — 15 reports (9.38%)
7. Pruritus — 15 reports (9.38%)
8. Renal Impairment — 14 reports (8.75%)
9. Bradycardia — 13 reports (8.12%)
10. Dizziness — 13 reports (8.12%)

Source database →

Frequently asked questions

Is Perindopril + Indapamide approved in United States?

Perindopril + Indapamide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Perindopril + Indapamide in United States?

Centre for Chronic Disease Control, India is the originator. The local marketing authorisation holder may differ — check the official source linked above.